Reference Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Ref Type
PMID (37815132)
Authors Joshi SK, Pittsenbarger J, Kennedy VE, Peretz CAC, Perl AE, Smith CC, Tyner JW, Druker BJ, Traer E
Title The FLT3N701K mutation causes clinical AML resistance to gilteritinib and triggers TKI sensitivity switch to quizartinib.
Journal Vol Issue Date Pages Journal Short Title
American journal of hematology 98 12 2023 Dec E364-E368 Am J Hematol
URL
Abstract Text

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Molecular Profile Treatment Approach
Gene Name Source Synonyms Protein Domains Gene Description Gene Role
Therapy Name Drugs Efficacy Evidence Clinical Trials
Drug Name Trade Name Synonyms Drug Classes Drug Description
Gene Variant Impact Protein Effect Variant Description Associated with drug Resistance
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
FLT3 exon 14 ins FLT3 N701K acute myeloid leukemia resistant Crenolanib Preclinical - Patient cell culture Actionable In a preclinical study, a patient-derived acute myeloid leukemia cell line harboring a FLT3-ITD mutation and FLT3 N701K was resistant to Crenolanib (CP-868596) in culture (PMID: 37815132). 37815132
FLT3 exon 14 ins FLT3 N701K acute myeloid leukemia resistant Midostaurin Preclinical - Patient cell culture Actionable In a preclinical study, a patient-derived acute myeloid leukemia cell line harboring a FLT3-ITD mutation and FLT3 N701K was resistant to Rydapt (midostaurin) in culture (PMID: 37815132). 37815132
FLT3 exon 14 ins FLT3 N701K acute myeloid leukemia sensitive FF-10101 Preclinical - Patient cell culture Actionable In a preclinical study, FF-10101 inhibited viability of a patient-derived acute myeloid leukemia cell line harboring a FLT3-ITD mutation and FLT3 N701K in culture (PMID: 37815132). 37815132
FLT3 exon 14 ins FLT3 N701K acute myeloid leukemia predicted - resistant Gilteritinib + Venetoclax Case Reports/Case Series Actionable In a clinical case study, FLT3 N701K was identified upon progression with Xospata (gilteritinib) and Venclexta (venetoclax) combination treatment in a patient with relapsed acute myeloid leukemia harboring a FLT3-ITD mutation (PMID: 37815132). 37815132
FLT3 exon 14 ins FLT3 N701K acute myeloid leukemia predicted - resistant Azacitidine + Gilteritinib Case Reports/Case Series Actionable In a clinical case study, FLT3 N701K was identified upon progression with Xospata (gilteritinib) and Vidaza (azacitidine) combination treatment in a patient with relapsed acute myeloid leukemia harboring a FLT3-ITD mutation (PMID: 37815132). 37815132
FLT3 exon 14 ins FLT3 N701K hematologic cancer sensitive FF-10101 Preclinical - Cell culture Actionable In a preclinical study, FF-10101 treatment inhibited viability of cells expressing a FLT3-ITD mutation and FLT3 N701K in culture (PMID: 37815132). 37815132